Cart
sales@molnova.com
BMS 599626 2HCl
CAS No. ——
BMS 599626 2HCl ( AC480 dihydrochloride )
Catalog No. M20147 CAS No. ——
BMS-599626 (AC480) is a selective inhibitor of HER1 and HER2 (IC50s: 20 nM and 30 nM) ~8-fold less potent to HER4 >100-fold to Lck VEGFR2 c-Kit MET etc.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 123 | Get Quote |
|
| 25MG | 411 | Get Quote |
|
| 50MG | 659 | Get Quote |
|
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameBMS 599626 2HCl
-
NoteResearch use only, not for human use.
-
Brief DescriptionBMS-599626 (AC480) is a selective inhibitor of HER1 and HER2 (IC50s: 20 nM and 30 nM) ~8-fold less potent to HER4 >100-fold to Lck VEGFR2 c-Kit MET etc.
-
DescriptionBMS-599626 (AC480) is a selective inhibitor of HER1 and HER2 (IC50s: 20 nM and 30 nM) ~8-fold less potent to HER4 >100-fold to Lck VEGFR2 c-Kit MET etc.
-
In Vitro——
-
In Vivo——
-
SynonymsAC480 dihydrochloride
-
PathwayAngiogenesis
-
TargetHER/HSP
-
RecptorHER1| HER2| HER4
-
Research AreaCancer
-
IndicationBreast Cancer; Glioma; Non-small cell lung Cancer; Solid tumours
Chemical Information
-
CAS Number——
-
Formula Weight603.47
-
Molecular FormulaC27H29Cl2FN8O3
-
Purity>98% (HPLC)
-
SolubilityDMSO: 95 mg/mL (167.55 mM);Water: 3 mg/mL
-
SMILESCl.Cl.Cc1c(NC(=O)OC[C@@H]2COCCN2)cn2ncnc(Nc3ccc4n(Cc5cccc(F)c5)ncc4c3)c12
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Wong TW et al. Preclinical antitumor activity of BMS-599626 a pan-HER kinase inhibitor that inhibits HER1/HER2 homodimer and heterodimer signaling. Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6186-93.
molnova catalog
related products
-
BMS 599626 2HCl (873...
BMS 599626 2HCl (873837-23-1(HCl)) (AC480 dihydrochloride) is a selective inhibitor of HER1 and HER2 (IC50s: 20 nM and 30 nM), ~8-fold less potent to HER4, >100-fold to Lck, VEGFR2, c-Kit, MET, etc.
-
NP10679
NP10679 is an orally available, selective, brain-penetrating, potent, and pH-sensitive N-methyl-D-aspartate (NMDA) receptor inhibitor of the GluN2B subunit.
-
Trastuzumab
Trastuzumab is a humanized monoclonal antibody for patients with invasive breast cancers that overexpress HER2. Trastuzumab has been clinically used to treat HER2 Positive Metastatic Breast Cancer and HER2 Positive Gastric Cancer.
